American International Group Inc. grew its holdings in Inogen, Inc (NASDAQ:INGN) by 6.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,480 shares of the medical technology company’s stock after purchasing an additional 829 shares during the period. American International Group Inc. owned approximately 0.06% of Inogen worth $1,282,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Piedmont Investment Advisors LLC purchased a new stake in shares of Inogen in the second quarter valued at $336,000. Parametric Portfolio Associates LLC lifted its holdings in shares of Inogen by 63.6% in the second quarter. Parametric Portfolio Associates LLC now owns 45,969 shares of the medical technology company’s stock valued at $4,386,000 after purchasing an additional 17,867 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Inogen by 24.9% in the second quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock valued at $144,594,000 after purchasing an additional 301,737 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Inogen by 4.7% in the second quarter. Bank of New York Mellon Corp now owns 293,070 shares of the medical technology company’s stock valued at $27,964,000 after purchasing an additional 13,160 shares in the last quarter. Finally, Koch Industries Inc. lifted its holdings in shares of Inogen by 19,485.8% in the second quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after purchasing an additional 653,747 shares in the last quarter.

Shares of Inogen, Inc (INGN) opened at $122.12 on Friday. Inogen, Inc has a 1-year low of $62.69 and a 1-year high of $130.05. The stock has a market capitalization of $2,493.80, a price-to-earnings ratio of 97.15, a P/E/G ratio of 5.02 and a beta of 1.13.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.04. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The business had revenue of $69.00 million during the quarter, compared to analyst estimates of $63.55 million. During the same period last year, the company earned $0.25 earnings per share. Inogen’s quarterly revenue was up 26.8% compared to the same quarter last year. sell-side analysts expect that Inogen, Inc will post 1.19 EPS for the current fiscal year.

In related news, EVP Matt Scribner sold 2,500 shares of the stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $93.88, for a total transaction of $234,700.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Alison Bauerlein sold 15,000 shares of the stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $94.93, for a total value of $1,423,950.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 84,000 shares of company stock valued at $9,128,405. 5.31% of the stock is owned by corporate insiders.

INGN has been the subject of a number of research analyst reports. Leerink Swann restated an “outperform” rating and issued a $120.00 target price (up previously from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Piper Jaffray Companies restated a “hold” rating and issued a $90.00 target price on shares of Inogen in a report on Tuesday, September 12th. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $131.00 target price for the company in a report on Thursday, November 9th. Needham & Company LLC restated a “buy” rating and issued a $108.00 target price on shares of Inogen in a report on Friday, September 1st. Finally, BidaskClub lowered Inogen from a “buy” rating to a “hold” rating in a report on Tuesday, December 5th. Four analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $103.14.

ILLEGAL ACTIVITY WARNING: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/12/17/inogen-inc-ingn-shares-bought-by-american-international-group-inc.html.

Inogen Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.